Investor Presentation H1 2023
160
Investor presentation
First six months of 2023
In the US, net prices have declined in the last five years
The US population by health insurance
coverage
7%
150
Insulin net prices¹ have declined
120
100
47%
00
90
46%
60
60
30
150
Net prices¹ across the full Novo
Nordisk portfolio² declined
120
101
100
90
90
52
60
60
30
30
Novo NordiskⓇ
106
65
333 million people
0
0
2019
2020
2021
2022
2019
2020
2021
2022
Uninsured
Private insurance schemes
List price
-
Net price
List price
Net price
Goverment insurance schemes
¹Percentage change represents a sales weighted average list and net price for the respective calendar year compared to the sales weighted average list and net price for the prior year, indexed to base year 2019, and is not
reflective of the magnitude of individual list price actions 2NN US Product Portfolio is inclusive of Diabetes, Obesity and Rare disease products
Government insurance schemes cover Medicare, Medicaid and public exchanges, some of these with high deductibles.
Source: Novo Nordisk Annual Report 2022 (illustration created from figures presented on page 89)View entire presentation